Alnylam Files for Initial Public Offering | GenomeWeb

Alnylam Files for Initial Public Offering

Mar 01, 2004

NEW YORK, March 1 (GenomeWeb News) - Alnylam Pharmaceuticals has filed a statement with the SEC for an initial public offering, the company said Friday evening.

The number of shares of common stock Alnylam plans to offer, and their price, have yet to be determined. Bank of America Securities serves as the company's book-runner and lead manager.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Best Options

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

A Butterfly's Wings

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

This Week in PNAS

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Pathogen Tracking

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.